{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:48:59Z","timestamp":1789469339901,"version":"build-2803163510"},"reference-count":29,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"9","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Clin Cancer Inform"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n            <jats:title>PURPOSE<\/jats:title>\n            <jats:p>Breast cancer (BC) is a leading cause of morbidity and mortality among women. Symptoms and treatment-related side effects often go undetected during routine follow-ups. Digital health interventions offer promising tools for real-time monitoring and personalized care. We aimed to implement and evaluate the feasibility of a mobile health electronic Patient-Reported Outcomes (ePRO)\u2013based platform for telemonitoring patients with BC undergoing (neo)adjuvant chemotherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS<\/jats:title>\n            <jats:p>\n              This prospective observational study enrolled patients with BC (TNM stages I to III) initiating chemotherapy at Barretos Cancer Hospital in Brazil. Participants were telemonitored using the\n              <jats:italic toggle=\"yes\">ThummiOnco<\/jats:italic>\n              platform for 4-6 months, following a standardized protocol. Feasibility was assessed through platform usage, resolution of patient-reported symptoms (according to Common Terminology Criteria for Adverse Events) within 48-72 hours, and health care outcomes, including additional consultations, dose reductions, treatment interruptions\/discontinuations, hospitalizations, and mortality. Statistical analysis was performed using descriptive statistics.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>Between October 2022 and June 2023, 67 eligible patients (median age 51 years) were included, with 62% receiving neoadjuvant chemotherapy. The median number of app accesses per patient was 38, with 6.65 daily symptom reports and 94% adherence. At 48 hours, 67% of patient-reported symptoms were fully resolved, whereas at 72 hours the resolution rate was 75.4%. Regarding resolution by grade, 83% of grade 1, 69.5% of grade 2, and 54.8% of grade 3 symptoms were fully resolved. Complementary consultations were needed for 34 patients. Dose reductions occurred in 10 (14.9%), treatment interruptions\/discontinuations in 35 (52.2%), and hospitalizations in seven (10.4%). One patient died from progressive disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>Telemonitoring facilitated early symptom identification and management. Most reports were resolved through the platform, with minimal additional demands on the health care team. Future studies should assess cost-effectiveness and scalability across diverse populations.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1200\/cci-25-00018","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T20:01:20Z","timestamp":1755115280000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":1,"title":["Feasibility and Implementation of a Digital Health Intervention Electronic Patient-Reported Outcomes\u2013Based Platform for Telemonitoring Patients With Breast Cancer Undergoing Chemotherapy"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4733-2080","authenticated-orcid":true,"given":"Daniela Donadon","family":"de Oliveira Rodrigues","sequence":"first","affiliation":[{"name":"Telehealth Department, Barretos Cancer Hospital, Barretos, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca Sakamoto","family":"Ribeiro Paiva","sequence":"additional","affiliation":[{"name":"Palliative Care and Quality of Life Research Group, Graduate Program, Barretos Cancer Hospital, Barretos, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domicio Carvalho","family":"Lacerda","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Barretos Cancer Hospital, Barretos, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9rgio Vicente","family":"Serrano","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Barretos Cancer Hospital, Barretos, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0744-4523","authenticated-orcid":true,"given":"Alessandra Menezes","family":"Morelle","sequence":"additional","affiliation":[{"name":"Thummi Global, Porto Alegre, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6021-667X","authenticated-orcid":true,"given":"Carlos","family":"Barrios","sequence":"additional","affiliation":[{"name":"Thummi Global, Porto Alegre, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8972-7449","authenticated-orcid":true,"given":"Matheus Soares","family":"Rocha","sequence":"additional","affiliation":[{"name":"Thummi Global, Porto Alegre, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8394-6042","authenticated-orcid":true,"given":"Paulo Alfredo","family":"Casanova Schulze","sequence":"additional","affiliation":[{"name":"Thummi Global, Porto Alegre, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7934-1451","authenticated-orcid":true,"given":"Carlos Eduardo","family":"Paiva","sequence":"additional","affiliation":[{"name":"Palliative Care and Quality of Life Research Group, Graduate Program, Barretos Cancer Hospital, Barretos, Brazil"},{"name":"Department of Clinical Oncology, Barretos Cancer Hospital, Barretos, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32381-3"},{"key":"e_1_3_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00285-4"},{"key":"e_1_3_7_4_2","first-page":"5943","article-title":"Real-world data of the association between quality of life using the EuroQol 5 Dimension 5 Level utility value and adverse events for outpatient cancer chemotherapy","volume":"28","author":"Hirose C","year":"2020","unstructured":"Hirose C, Fujii H, Iihara H, et al: Real-world data of the association between quality of life using the EuroQol 5 Dimension 5 Level utility value and adverse events for outpatient cancer chemotherapy. Support Care Cancer 28:5943-5952, 2020","journal-title":"Support Care Cancer"},{"key":"e_1_3_7_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000021695"},{"key":"e_1_3_7_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae150"},{"key":"e_1_3_7_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djj305"},{"key":"e_1_3_7_8_2","doi-asserted-by":"crossref","first-page":"e066588","DOI":"10.1136\/bmj-2021-066588","article-title":"Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: Pragmatic, cluster randomised trial","volume":"375","author":"Krzyzanowska MK","year":"2021","unstructured":"Krzyzanowska MK, Julian JA, Gu C-S, et al: Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: Pragmatic, cluster randomised trial. BMJ 375:e066588, 2021","journal-title":"BMJ"},{"key":"e_1_3_7_9_2","doi-asserted-by":"publisher","DOI":"10.2196\/38333"},{"key":"e_1_3_7_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000697"},{"key":"e_1_3_7_11_2","doi-asserted-by":"publisher","DOI":"10.21037\/mhealth-23-15"},{"key":"e_1_3_7_12_2","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14060619"},{"key":"e_1_3_7_13_2","doi-asserted-by":"publisher","DOI":"10.3390\/mps7020024"},{"key":"e_1_3_7_14_2","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2021.02026"},{"key":"e_1_3_7_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01171"},{"key":"e_1_3_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.soncn.2023.151550"},{"key":"e_1_3_7_17_2","doi-asserted-by":"publisher","DOI":"10.2196\/48483"},{"key":"e_1_3_7_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.23.00498"},{"key":"e_1_3_7_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01788-1"},{"key":"e_1_3_7_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/pon.5797"},{"key":"e_1_3_7_21_2","first-page":"353","article-title":"The implementation of a mobile APP for cancer care management at the Brazilian national cancer Institute","volume":"289","author":"Pires ETC","year":"2022","unstructured":"Pires ETC, Cheng C, de Castro Silva SLF, et al: The implementation of a mobile APP for cancer care management at the Brazilian national cancer Institute. Stud Health Technol Inform 289:353-356, 2022","journal-title":"Stud Health Technol Inform"},{"key":"e_1_3_7_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.05.003"},{"key":"e_1_3_7_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02015"},{"key":"e_1_3_7_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.23_suppl.163"},{"key":"e_1_3_7_25_2","volume-title":"Protocol Development | CTEP","author":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE)","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE): Protocol Development | CTEP. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm"},{"key":"e_1_3_7_26_2","first-page":"85","article-title":"Estimating sample size and power","volume":"2","author":"Hulley S","year":"2001","unstructured":"Hulley S, Cummings S, Browner W, et al: Estimating sample size and power. Des Clin Res 2:85, 2001","journal-title":"Des Clin Res"},{"key":"e_1_3_7_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"e_1_3_7_28_2","doi-asserted-by":"publisher","DOI":"10.2196\/46189"},{"key":"e_1_3_7_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1647"},{"key":"e_1_3_7_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.22998"}],"container-title":["JCO Clinical Cancer Informatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/CCI-25-00018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T20:01:22Z","timestamp":1755115282000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/CCI-25-00018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1200\/CCI-25-00018"],"URL":"https:\/\/doi.org\/10.1200\/cci-25-00018","relation":{},"ISSN":["2473-4276"],"issn-type":[{"value":"2473-4276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"2025-01-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2500018"}}